We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CMS WON'T COVER ARTIFICIAL SPINE DISC REPLACEMENT DEVICE FOR OVER-60 CROWD

CMS WON'T COVER ARTIFICIAL SPINE DISC REPLACEMENT DEVICE FOR OVER-60 CROWD

July 11, 2006

The Centers for Medicare & Medicaid (CMS) June 23 announced its decision not to cover lumbar artificial disc replacement (LADR) with the ChariteTM artificial disc for Medicare beneficiaries over 60 years old.

The agency made its national coverage decision after completing a national coverage analysis. The policy went into effect May 16, and must be implemented by insurance carriers July 17 with full implementation by Oct. 1, the agency said.

LADR is a surgical procedure involving complete removal of a damaged or diseased lumbar intervertebral disc and implantation of an artificial disc. The procedure offers an alternative to lumbar spinal fusion and is intended to reduce pain, increase movement at the site of surgery and restore intervertebral disc height, the agency said.

The FDA has approved the use of the ChariteTM artificial disc, made by DePuy Spine, for spine arthroplasty in skeletally mature patients with degenerative or discogenic disc disease, the CMS said. Medicare coverage under the investigational device exemption for other lumbar artificial discs in eligible clinical trials is not affected, the CMS added.

The CMS decision can be viewed at www.cms.hhs.gov/transmittals/downloads/R60NCD.pdf (http://www.cms.hhs.gov/transmittals/downloads/R60NCD.pdf).

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 13Sep

    Trial Master File Inspection Readiness: From Chaos to Calm

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready?

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test

  • Genentech Inks Licensing Deal With Jemincare Over Androgen Receptor Degrader

  • FDA Clears Thermo Fisher Scientific’s Wheat and Sesame Allergy Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing